Role of Senescence in the Development of Endometrial Cancer

CHU de Reims

Status: Unknown

Conditions: Endometrial Hyperplasia and Endometrial Cancers

Treatments: Genetic: Genetic analysis

Study type: Interventional

Funder types: Other

Identifiers

NCT03338985

PA17002

Details and patient eligibility

About

Several molecular studies showed chromosomal alterations in patients with endometrial cancer, with gains in 1q, 19p, 19q, 8q, 10q and 10p and loss of 4q, 16q and 18q. Several genes of interest have been identified (P53, PTEN, PIK3CA, ß-catenin, K-ras ...).

A study has already been carried out at the Reims University Hospital with inclusion of patients with endometrial cancer and patients with endometrial hyperplasia. It identified specific alterations of nosologic continuum of pathology and characterize areas of interest on the genome.

Full description

make a pangenomic investigation of genetic abnormalities in atypical endometrial hyperplasia and endometrial cancers.

Enrollment: 140 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patient with endometrial hyperplasia or endometrial cancer
• patient consenting to participate to the study
• patient enrolled in the national healthcare insurance program
• patient older than 18 years

Exclusion criteria

• patient with neoadjuvant chemotherapy or radiotherapy prior to surgery

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

140 participants in 1 patient group

Group "cases patients"

Experimental group

Description:

patients with endometrial hyperplasia or endometrial cancers

Treatment:

Genetic: Genetic analysis